{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T15:47:11Z","timestamp":1777909631594,"version":"3.51.4"},"reference-count":39,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2010,3,24]],"date-time":"2010-03-24T00:00:00Z","timestamp":1269388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Ocular Pharmacology and Therapeutics"],"published-print":{"date-parts":[[2010,4,1]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>\n                      To determine the effectiveness of topically applied besifloxacin, gatifloxacin, and moxifloxacin for the early treatment of experimental methicillin-resistant\n                      <jats:italic toggle=\"yes\">Staphylococcus aureus<\/jats:italic>\n                      (MRSA) keratitis.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Ten hours post-MRSA infection, rabbit eyes were treated topically with 19 doses of phosphate-buffered saline (PBS), besifloxacin, gatifloxacin, or moxifloxacin. Slit-lamp examinations were performed before and after the inoculation. Corneas were harvested for bacterial quantitation and minimal inhibitory concentrations (MICs) were determined.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      All 3 fluoroquinolones significantly lowered the clinical severity of the infection as compared to treatment with PBS (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.05). However, the mean log\n                      <jats:sub>10<\/jats:sub>\n                      colony-forming unit (CFU) recovered from besifloxacin-treated corneas was significantly lower than all other treatment groups (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.01). CFU recovered from corneas treated with moxifloxacin and PBS showed no significant difference (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.12). Corneas treated with gatifloxacin had a significantly lower log\n                      <jats:sub>10<\/jats:sub>\n                      CFU recovered as compared to PBS-treated corneas (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.01). The MICs for gatifloxacin and moxifloxacin were 8 \u03bcg\/mL, whereas the MIC for besifloxacin was 1 \u03bcg\/mL.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>All 3 fluoroquinolones significantly lowered the clinical severity of the infection. Besifloxacin had an 8-fold lower MIC for MRSA than gatifloxacin and moxifloxacin, and was significantly more effective than gatifloxacin and moxifloxacin in reducing the number of MRSA in the rabbit cornea.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1089\/jop.2009.0121","type":"journal-article","created":{"date-parts":[[2010,3,24]],"date-time":"2010-03-24T14:47:33Z","timestamp":1269442053000},"page":"193-198","source":"Crossref","is-referenced-by-count":21,"title":["Efficacy of Besifloxacin in an Early Treatment Model of Methicillin-Resistant\n                    <i>Staphylococcus Aureus<\/i>\n                    Keratitis"],"prefix":"10.1177","volume":"26","author":[{"given":"Melissa E.","family":"Sanders","sequence":"first","affiliation":[{"name":"Department of Microbiology, University of Mississippi Medical Center, Jackson, Mississippi."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"III","given":"Quincy C.","family":"Moore","sequence":"additional","affiliation":[{"name":"Department of Microbiology, University of Mississippi Medical Center, Jackson, Mississippi."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erin W.","family":"Norcross","sequence":"additional","affiliation":[{"name":"Department of Microbiology, University of Mississippi Medical Center, Jackson, Mississippi."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Afshin","family":"Shafiee","sequence":"additional","affiliation":[{"name":"Pharmaceutical R & D, Bausch & Lomb, Rochester, New York."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary E.","family":"Marquart","sequence":"additional","affiliation":[{"name":"Department of Microbiology, University of Mississippi Medical Center, Jackson, Mississippi."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2010,3,24]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(00)00179-2"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1097\/00003226-198906000-00007"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.icl.0000234002.88643.d0"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2007.03.032"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.eye.6701465"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcrs.2005.12.108"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02351563"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.161272898"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(96)09229-X"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.299.6694.294"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkl017"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/.61.3.377-392.1997"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.3201\/eid0702.010239"},{"key":"e_1_3_3_15_2","article-title":"Clinical outcomes of methicillin resistant Staph aureus (MRSA) corneal infections resistant to fourth generation fluoroquinolones","volume":"47","author":"Rhee D.Y","year":"2006","unstructured":"Rhee D.Y, ., Gillespie W.B, ., and Soukiasian S.H. Clinical outcomes of methicillin resistant Staph aureus (MRSA) corneal infections resistant to fourth generation fluoroquinolones. Invest. Ophthalmol. Vis. Sci. 47:47\u201356, 2006.","journal-title":"Invest. Ophthalmol. Vis. Sci"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.30.6.823"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.3.938-942.2001"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00418-09"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.6.1948-1952.2004"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.07-0320"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1097\/ICO.0b013e31819e34cb"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.3109\/02713689008997584"},{"key":"e_1_3_3_23_2","first-page":"9","volume-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard","author":"Clinical and Laboratory Standards Institute","year":"2006","unstructured":"Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard. 7th ed. (document M7-A7). Wayne, PA: Clinical and Laboratory Standards Institute; 2006 ; p. 9\u201310, 16\u201317.","edition":"7"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0711767105"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(96)30416-8"},{"key":"e_1_3_3_26_2","first-page":"34S","article-title":"Clinical evaluation of ciprofloxacin 0.3% ophthalmic solution for treatment of bacterial keratitis","volume":"112","author":"Leibowitz H.M","year":"1991","unstructured":"Leibowitz H.M. Clinical evaluation of ciprofloxacin 0.3% ophthalmic solution for treatment of bacterial keratitis. Am. J. Ophthalmol. 112:34S\u201347S, 1991.","journal-title":"Am. J. Ophthalmol"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(97)30009-8"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(88)92799-7"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.33.1.128"},{"key":"e_1_3_3_30_2","first-page":"3017","article-title":"Topical antibiotic therapy for the treatment of experimental Staphylococcus aureus keratitis","volume":"33","author":"Callegan M.C","year":"1992","unstructured":"Callegan M.C, ., Hobden J.A, ., Hill J.M ., et al. Topical antibiotic therapy for the treatment of experimental Staphylococcus aureus keratitis. Invest. Ophthalmol. Vis. Sci. 33:3017\u20133023, 1992.","journal-title":"Invest. Ophthalmol. Vis. Sci"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.3109\/02713689209015083"},{"key":"e_1_3_3_32_2","first-page":"1033","article-title":"Ciprofloxacin versus tobramycin for the treatment of staphylococcal keratitis","volume":"35","author":"Callegan M.C","year":"1994","unstructured":"Callegan M.C, ., Engel L.S, ., Hill J.M ., et al. Ciprofloxacin versus tobramycin for the treatment of staphylococcal keratitis. Invest. Ophthalmol. Vis. Sci. 35:1033\u20131037, 1994.","journal-title":"Invest. Ophthalmol. Vis. Sci"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.1995.01100100045026"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.04.00109704"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9394(86)90820-2"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1128\/iai.65.5.1571-1578.1997"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1080\/02713680802478704"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkm398"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1185\/03007990902837919"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2009.03.010"}],"container-title":["Journal of Ocular Pharmacology and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/jop.2009.0121","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/jop.2009.0121","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/jop.2009.0121","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T14:35:52Z","timestamp":1777646152000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/jop.2009.0121"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,3,24]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010,4,1]]}},"alternative-id":["10.1089\/jop.2009.0121"],"URL":"https:\/\/doi.org\/10.1089\/jop.2009.0121","relation":{},"ISSN":["1080-7683","1557-7732"],"issn-type":[{"value":"1080-7683","type":"print"},{"value":"1557-7732","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,3,24]]}}}